Drug Approval | February 22, 2022
The facility will manufacture its Herceptin biosimilar, Tuznue
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Subscribe To Our Newsletter & Stay Updated
